Amgen vs Merck & Company at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | AMGN | MRK |
|---|---|---|
| Market cap | $241.45B | $372.43B |
| Price | $442.24 | $156.45 |
| P/E ratio (TTM) | 22.89 | 14.18 |
| P/B ratio (MRQ) | 20.38 | 4.92 |
| P/S ratio (TTM) | 4.8 | 3.98 |
| Revenue growth (1Y) | 9.92% | 1.31% |
| Return on equity (TTM) | 89.06% | 34.70% |
| Return on invested capital (TTM) | 14.50% | 22.71% |
| Gross margin (TTM) | 72.65% | 82.44% |
| Net margin (TTM) | 22.93% | 13.59% |
| Dividend yield (TTM) | 2.27% | 2.26% |
How they differ
Merck & Company is the larger company at $372.43B versus $241.45B — about 1.5x the size.
On trailing earnings, Merck & Company is the cheaper of the two at 14.18 against 22.89 for Amgen.
On sales, Merck & Company is the cheaper of the two at 3.98 against 4.8 for Amgen.
Amgen leads on revenue growth over the past year, 9.92% against 1.31%.
Merck & Company leads on return on invested capital, 22.71% against 14.50%.
Merck & Company leads on gross margin, 82.44% against 72.65%.
Amgen offers the higher yield at 2.27% against 2.26%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Amgen or Merck & Company.